



Professor Daniel Palmer

BSc MBChB FRCP PhD

Prof Palmer was appointed Northwest Cancer Research Chair in Medical Oncology at the University of Liverpool in 2011. His research interests relate to **Hepatobiliary (HPB) cancers (liver, pancreas and biliary tract)**. Prof Palmer is director of the Liverpool Experimental Cancer Medicine Centre (ECMC), a collaboration between The Clatterbridge Cancer Centre, Liverpool Clinical Trials Centre and the University of Liverpool. In 2023 Prof Palmer was appointed as a clinical lead working with NHS England's Getting It Right First Time (GIRFT) programme, reviewing services for pancreatic cancer patients.

Prof Palmer has undertaken Medicolegal work for 10 years. He accepts approximately 30 cases per year relating to clinical negligence in **diagnosis and treatment of HPB cancers, and neuroendocrine tumours**.

GMC 4195311



Institute of Systems,
Molecular and
Integrative Biology,
University of Liverpool,
Crown St, L69 7BE

[Present Appointments](#)

Liverpool Experimental Cancer Medicine Centre, 2017 - Present
Director

University of Liverpool, 2011 – Present
North West Cancer Research Professor of Medical Oncology,

Clatterbridge Cancer Centre
Honorary Consultant in Medical Oncology

[Employment History](#)

Oct 2010 – Mar 2011
Senior Lecturer in Medical Oncology • University of Birmingham

Sept 2005 – Sept 2010
Cancer Research UK Clinician Scientist • University of Birmingham

[Education](#)

FRCP, 2008
Royal College of Physicians of London

PhD, 2004
Cancer Studies, University of Birmingham

MRCP, 1998
Royal College of Physicians of London



MBChB, 1995

University of Birmingham

BSc (Hons) Pathological Studies (1st Class), 1994

University of Birmingham

Leadership Roles & Committee Memberships

Director • Liverpool CR UK/NIHR Experimental Cancer Medicine Centre
Deputy Director • Liverpool CR UK Clinical Trials Unit
Member • NCRI Upper GI Cancers Clinical Studies Group
Member • NCRI Pancreas Cancer Subgroup
Member • NCRI Hepatobiliary Cancers Subgroup
Member • American Society of Clinical Oncology
Association of Cancer Physicians McElwain Scholarship • 2005
Member and/or Chair multiple IDMC and Dose Escalation Committees for early and late phase clinical trials

Publications

Over 100 publications in peer-reviewed journals including: New England Journal of Medicine; Lancet; JAMA; Lancet Oncology; Journal of Clinical Oncology; J Natl Cancer Inst; Cancer Research; Cancer Discovery; Lancet Gastro Hep; Hepatology; J Hepatol; Br J Cancer

Recent Grants

2023 – 2028

CRUK/NIHR Liverpool Experimental Cancer Medicine Centre • £1,500,000 • (PI)

2019 – 2024

Astra Zeneca. RaTIO: A platform study of immunotherapy in combination with different radiotherapy modalities for patients with advanced hepatocellular carcinoma • £1,250,000 • (PI)

2017 – 2024


BMS TACE-3: A Randomised Phase II/III clinical trial of TACE +/- nivolumab in patients with intermediate stage hepatocellular carcinoma • £4,083,253 • (PI)


2017 – 2022

CRUK/NIHR Liverpool Experimental Cancer Medicine Centre. £1,500,000 • (PI)

2015 – 2019

A20220: ACELARATE - A Phase III, open label, multicentre randomized clinical trial comparing Acelarin with Gemcitabine in patients with





metastatic pancreatic adenocarcinoma • CRUKE/15/013 • £1,390,000 • (PI) • Funding Nucana; CTAAC endorsed)

2017 – 2020

CRUK Multi-disciplinary Research Award: Development of nano-medicines • £430,000 Palmer DH and Rannard S • (Co-PI)

[References](#)

[Available upon request.]

